LABOPHARM/PURDUE PHARMA SIGN TRAMADOL LICENSING PACT.
Labopharm Inc. (TSX: DDS), Laval, Quebec, and Purdue Pharma L.P.,
Stamford, Conn., has signed a definitive licensing and distribution
agreement under which Labopharm, through its subsidiary, . . .
PHASE IIB STUDY SHOWS REVERSET ACHIEVES ANTIVIRIRAL
BENEFIT.
Incyte Corporation (Nasdaq:INCY) has announced positive results
from Study 203, a six-month randomized double-blind Phase IIb trial,
involving 199 patients and 25 clinical sites in the U.S. and . . .
VALEANT BEGINS CLINICAL DEVELOPMENT OF VIRAMIDINE IN
JAPAN.
Valeant Pharmaceuticals International (NYSE:VRX), Costa Mesa,
Calif., plans to initiate the development of Viramidine(R) in Japan
following the first meeting of the company's hepatitis C . . .
OSI INITIATES PHASE I CLINICAL TRIAL OF PSN357.
OSI Pharmaceuticals (Nasdaq: OSIP), Melville, N.Y., has initiated a
Phase I clinical study of PSN357. Discovered by (OSI) Prosidion,
OSI's diabetes and obesity team, PSN357 is a glycogen . . .
ONCOGENEX BEGINS FIRST OF 4 PHASE 2 CLINICAL 0GX-011
TRIALS.
OncoGenex Technologies Inc., Vancouver, has initiated a Phase 2
clinical trial of OGX-011 in newly diagnosed, previously untreated
patients with clinically localized, high-risk prostate . . .
NEUROBIOLOGICAL TECHNOLOGIES SIGNS VIPRINEX PACTS.
Neurobiological Technologies, Inc. (NTI) (NASDAQ:NTII) has signed
agreements with Nordmark Arzneimittel GmbH & Co KG (Nordmark) and
Baxter Pharmaceutical Solutions, LLC (Baxter) to manufacture, . . .
PHARMASSET TO DEVELOP CLEVUDINE FOR HEPATITIS B.
Pharmasset, Inc. and Bukwang Pharm. Co., Ltd. have entered into an
exclusive license agreement under which Pharmasset will develop and
commercialize Clevudine, also known as L-FMAU, for the . . .
UPSTATE GROUP/CXR BIOSCIENCES DEVELOPING IN VITRO
SCREENS.
Serologicals Corporation (NASDAQ: SERO) has announced that Upstate
Group, its wholly owned subsidiary, has initiated a collaboration with
CXR Biosciences to establish a battery of proprietary in . . .
BARRIER ACQUIRES VANIQA CANADIAN DISTRIBUTION RIGHTS.
Barrier Therapeutics, Inc. (NASDAQ: BTRX), Princeton, N.J., a
pharmaceutical company developing products in the field of dermatology,
has acquired the right to distribute VANIQA(r) . . .
SFDA GRANTS MIRACLE LASER APPROVAL TO SELL SYNERON
PRODUCTS.
Syneron Medical Ltd. (Nasdaq:ELOS), Yokneam, Israel, and its
Chinese distributor, Miracle Laser, have announced that the State Food
& Drug Administration (SFDA) of the People's Republic of . . .
BIOCUREX/GOSHEN CANCER CENTER DEVELOPING RECAF.
BioCurex Inc., Richmond, British Columba, has initiated a
collaboration with the Center for Cancer Care in Goshen, Indiana, for
developing and evaluating its RECAF(tm) technology.
The . . .
NEWLY-ENGINEERED SYNTHETIC AFGP STABLE/NON-TOXIC.
The University of Rouen in France has reported that their
laboratory has completed an enzymatic study on the dimeric compound of
synthetic AFGP, which resulted in zero degradation. This . . .
ISOLAGEN UNVEILS AUTOMATED CELLULAR EXPANSION SYSTEM.
Isolagen, Exton, Pa., which specializes in the development and
commercialization of autologous cellular therapies for tissue
regeneration, has unveiled a design for an automated system to . . .
QIAGEN LAUNCHES PRODUCT PORTFOLIO FOR RNAI/SYBR RT-PCR.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA), Venlo,
The Netherlands, a provider of innovative enabling technologies and
products for the separation, purification and handling of . . .
GPC BIOTECH PRESENTS NEW SATRAPLATIN DATA AT AACR.
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index;
NASDAQ: GPCB) has announced that the company presented data on its lead
drug candidate satraplatin at the 96th Annual Meeting of the . . .
STUDIES SUPPORT LIPID SCIENCES VIRAL IMMUNOTHERAPY
PLATFORM.
Lipid Sciences, Inc. (Nasdaq:LIPD), Pleasanton, Calif., has
announced that the latest results of both in vivo and in vitro studies
supporting the company's Viral Immunotherapy Platform have . . .
RECAF BLOOD TEST DETECTS 92% OF CERVICAL CANCERS.
BioCurex, Inc. (Pink Sheets:BOCX), Richmond, B.C., Canada, has
completed a study in which its RECAF blood test detected 92% of cervical
cancers using a drop of blood. The specificity of the test . . .
MONSANTO ENCOURAGED BY BRAZILIAN BIOSAFETY LAW.
Brazil's President Lula has recently signed a biosafety bill
into law which establishes the regulatory process for the approval of
biotech crops. This step is another indication of the growing . . .
ALLERGAN/SANWA KAGAKU KENKYUSHO TO DEVELOP POSURDEX IN
JAPAN.
Allergan, Inc. (NYSE:AGN), Irvine, Calif., has entered into an
exclusive licensing agreement with Sanwa Kagaku Kenkyusho Co., Ltd.
(Sanwa) to develop and commercialize POSURDEX(R) for the . . .
INDIA AND CII SUPPORT AETHLON HIV/HEPATITIS TRIALS.
Aethlon Medical, Inc. (OTCBB:AEMD), San Diego, has been advised by
Qualtran LLC, a contract research organization (CRO) managing clinical
trials for Aethlon in India, that both the Government of . . .
|
|